These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 22449610

  • 1. Allogeneic hematopoietic cell transplantation for advanced polycythemia vera and essential thrombocythemia.
    Ballen KK, Woolfrey AE, Zhu X, Ahn KW, Wirk B, Arora M, George B, Savani BN, Bolwell B, Porter DL, Copelan E, Hale G, Schouten HC, Lewis I, Cahn JY, Halter J, Cortes J, Kalaycio ME, Antin J, Aljurf MD, Carabasi MH, Hamadani M, McCarthy P, Pavletic S, Gupta V, Deeg HJ, Maziarz RT, Horowitz MM, Saber W.
    Biol Blood Marrow Transplant; 2012 Sep; 18(9):1446-54. PubMed ID: 22449610
    [Abstract] [Full Text] [Related]

  • 2. Allogeneic Hematopoietic Stem Cell Transplantation for Post-essential Thrombocythemia and Post-polycythemia Vera Myelofibrosis.
    Murata M, Suzuki R, Nishida T, Shirane S, Shimazu Y, Minami Y, Mori T, Doki N, Kanda Y, Uchida N, Tanaka M, Ishikawa J, Togitani K, Fukuda T, Ichinohe T, Atsuta Y, Nagamura-Inoue T, Kiyoi H.
    Intern Med; 2020 Sep; 59(16):1947-1956. PubMed ID: 32801269
    [Abstract] [Full Text] [Related]

  • 3. Curative therapy of advanced essential thrombocythemia or polycythemia vera by hemopoietic stem cell transplantation.
    Platzbecker U, Gooley T, Anasetti C, Appelbaum FR, Clurman B, Doney K, Chauncey T, Flowers ME, Myerson D, Radich JP, Storb R, Witherspoon RP, Deeg HJ.
    Leuk Lymphoma; 2002 Jul; 43(7):1409-14. PubMed ID: 12389621
    [Abstract] [Full Text] [Related]

  • 4. Comparison of Dynamic International Prognostic Scoring System and MYelofibrosis SECondary to PV and ET Prognostic Model for Prediction of Outcome in Polycythemia Vera and Essential Thrombocythemia Myelofibrosis after Allogeneic Stem Cell Transplantation.
    Gagelmann N, Eikema DJ, de Wreede LC, Koster L, Wolschke C, Arnold R, Kanz L, McQuaker G, Marchand T, Socié G, Bourhis JH, Mohty M, Cornelissen JJ, Chevallier P, Bernasconi P, Stelljes M, Rohrlich PS, Fanin R, Finke J, Maertens J, Blaise D, Itälä-Remes M, Labussière-Wallet H, Robin M, McLornan D, Chalandon Y, Yakoub-Agha I, Kröger N, CMWP of the European Society for Blood and Marrow Transplantation.
    Biol Blood Marrow Transplant; 2019 Jun; 25(6):e204-e208. PubMed ID: 30930192
    [Abstract] [Full Text] [Related]

  • 5. Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia.
    Kerbauy DM, Gooley TA, Sale GE, Flowers ME, Doney KC, Georges GE, Greene JE, Linenberger M, Petersdorf E, Sandmaier BM, Scott BL, Sorror M, Stirewalt DL, Stewart FM, Witherspoon RP, Storb R, Appelbaum FR, Deeg HJ.
    Biol Blood Marrow Transplant; 2007 Mar; 13(3):355-65. PubMed ID: 17317589
    [Abstract] [Full Text] [Related]

  • 6. Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: a report from the MPN Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation.
    Lussana F, Rambaldi A, Finazzi MC, van Biezen A, Scholten M, Oldani E, Carobbio A, Iacobelli S, Finke J, Nagler A, Volin L, Lamy T, Arnold R, Mohty M, Michallet M, de Witte T, Olavarria E, Kröger N.
    Haematologica; 2014 May; 99(5):916-21. PubMed ID: 24389309
    [Abstract] [Full Text] [Related]

  • 7. Allogeneic Stem Cell Transplantation in Myelofibrosis.
    Jain T, Mesa RA, Palmer JM.
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1429-1436. PubMed ID: 28499938
    [Abstract] [Full Text] [Related]

  • 8. Leukocytosis in polycythemia vera and splenomegaly in essential thrombocythemia are independent risk factors for hemorrhage.
    Chou YS, Gau JP, Yu YB, Pai JT, Hsiao LT, Liu JH, Hong YC, Liu CY, Yang CF, Chen PM, Chiou TJ, Tzeng CH.
    Eur J Haematol; 2013 Mar; 90(3):228-36. PubMed ID: 23281576
    [Abstract] [Full Text] [Related]

  • 9. Allogeneic hematopoietic stem cell transplantation for myelofibrosis.
    Deeg HJ, Gooley TA, Flowers ME, Sale GE, Slattery JT, Anasetti C, Chauncey TR, Doney K, Georges GE, Kiem HP, Martin PJ, Petersdorf EW, Radich J, Sanders JE, Sandmaier BM, Warren EH, Witherspoon RP, Storb R, Appelbaum FR.
    Blood; 2003 Dec 01; 102(12):3912-8. PubMed ID: 12920019
    [Abstract] [Full Text] [Related]

  • 10. Haemopoietic stem cell transplantation for advanced polycythaemia vera or essential thrombocythaemia.
    Jurado M, Deeg H, Gooley T, Anasetti C, Chauncey T, Flowers M, Myerson D, Storb R, Appelbaum F.
    Br J Haematol; 2001 Feb 01; 112(2):392-6. PubMed ID: 11167837
    [Abstract] [Full Text] [Related]

  • 11. Splenic irradiation as a component of a reduced-intensity conditioning regimen for hematopoietic stem cell transplantation in myelofibrosis with massive splenomegaly.
    Ito T, Akagi K, Kondo T, Kawabata H, Ichinohe T, Takaori-Kondo A.
    Tohoku J Exp Med; 2012 Dec 01; 228(4):295-9. PubMed ID: 23117264
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Thrombohemorrhagic events, disease progression, and survival in polycythemia vera and essential thrombocythemia: a retrospective survey in Miyazaki prefecture, Japan.
    Kamiunten A, Shide K, Kameda T, Sekine M, Kubuki Y, Ito M, Toyama T, Kawano N, Marutsuka K, Maeda K, Takeuchi M, Kawano H, Sato S, Ishizaki J, Akizuki K, Tahira Y, Shimoda H, Hidaka T, Yamashita K, Matsuoka H, Shimoda K.
    Int J Hematol; 2018 Jun 01; 107(6):681-688. PubMed ID: 29488167
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Reducing Treatment-Related Mortality Did Not Improve Outcomes of Allogeneic Myeloablative Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma: A University of Michigan Prospective Series.
    Pawarode A, Mineishi S, Reddy P, Braun TM, Khaled YA, Choi SW, Magenau JM, Harris AC, Connelly JA, Kitko CL, Parkin BL, Goldstein SC, Yanik GA, Levine JE, Ferrara JL, Couriel DR.
    Biol Blood Marrow Transplant; 2016 Jan 01; 22(1):54-60. PubMed ID: 26211984
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.